Cabergoline associated with first episode mania

Psychosomatics

Volumn 53, Issue 6, 2012, Pages 595-600

  Harris, Yael T ^a,b   Harris, Alexander Z ^c   deAsis, Jose M ^c   Ferrando, Stephen J ^c   Reddy, Nirmala ^d   Young, Robert C ^c  

^a Northwell Health   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; HALOPERIDOL; LORAZEPAM; MULTIVITAMIN; QUETIAPINE; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYOPE; MANIA; SCHIZOPHRENIA; SUICIDE; TREATMENT OUTCOME;

AMENORRHEA; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DISEASE SUSCEPTIBILITY; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; TRANQUILIZING AGENTS; VALPROIC ACID;

EID: 84875808484     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2012.01.005     Document Type: Article

References (56)

1. Daily Med Current Medication Information 2010 National Library of Medicine, Accessed March 12, 2011. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=31309.
2. Molitch M.E. Medication-induced hyperprolactinemia. Mayo Clinic Proceedings 2005, 80(8):1050-1057.
3. Suppes T., Leverich G.S., Keck P.E., Nolen W.A., Denicoff K.D., Altshuler L.L., et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord 2001, 67(1/3):45-59.
4. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry: J Mental Sci 1978, 133:429-435.
5. Solomon D.A., Leon A.C., Coryell W.H., Endicott J., Li C., Fiedorowicz J.G., et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry 2010, 67(4):339-347.
6. Krauthammer C., Klerman G.L. Secondary mania: manic syndromes associated with antecedent physical illness or drugs. Arch Gen Psychiatry 1978, 35(11):1333-1339.
7. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245.
8. Rotondo A., Bosco D., Plastino M., Consoli A., Bosco F. Clozapine for medication-related pathologic gambling in Parkinson disease. Movement Dis: Official J Movement Dis Soc 2010, 25(12):1994-1995.
9. Davie M. Pathologic gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci 2007, 19(4):473-474.
10. Falhammar H., Yarker J.Y. Pathologic gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Australia 2009, 190(2):97.
11. eHealthMe, real world drug outcomes Accessed March 12, 2011. http://www.ehealthme.com/ds/cabergoline/mania.
12. Horowski R. A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease-a subjective view. J Neural Transm 2007, 114(1):127-134.
13. Sneader W. Drug discovery: a history 2005, Wiley, Hoboken, NJ.
14. Schatzberg A.F., Cole J.O., DeBattista C. Manual of clinical psychopharmacology 2010, American Psychiatric Pub, Washington, DC. 7th ed.
15. Schatzberg A.F., Nemeroff C.B. The American Psychiatric Publishing textbook of psychopharmacology 2009, American Psychiatric Pub, Washington, DC. 4th ed.
16. Aiken C.B. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007, 68(8):1230-1236.
17. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003, 16(Suppl 1):S3-S7.
18. Bonuccelli U., Pavese N. Role of dopamine agonists in Parkinson's disease: an update. Expert Rev Neurother 2007, 7(10):1391-1399.
19. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F., et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994, 331(14):904-909.
20. Hassan A., Bower J.H., Kumar N., Matsumoto J.Y., Fealey R.D., Josephs K.A., et al. Dopamine agonist-triggered pathologic behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism and Related Dis 2011, 17(4):260-264.
21. Ciccarelli A., Daly A.F., Beckers A. The epidemiology of prolactinomas. Pituitary 2005, 8(1):3-6.
22. Kendell R.E., Chalmers J.C., Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry: J Mental Sci 1987, 150:662-673.
23. Antonini A., Cilia R. Behavioral adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Safety: Int J Med Toxicol Drug Exp 2009, 32(6):475-488.
24. Marchand W.R., Bennett P.J., Dilda D.S. Evidence for frontal-subcortical circuit abnormalities in bipolar affective disorder. Psychiatry 2005, 2(4):26-33.
25. Goodwin F.K., Jamison K.R., Ghaemi S.N. Manic-depressive illness: bipolar disorders and recurrent depression 2007, Oxford University Press, New York, NY. 2nd ed.
26. Hollander E., Pallanti S., Baldini Rossi N., Sood E., Baker B.R., Buchsbaum M.S., et al. Imaging monetary reward in pathologic gamblers. World J Biol Psychiatry 2005, 6(2):113-120.
27. Bechara A., Damasio A.R., Damasio H., Anderson S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994, 50(1/3):7-15.
28. Taghzouti K., Le Moal M., Simon H. Enhanced frustrative nonreward effect following 6-hydroxydopamine lesions of the lateral septum in the rat. Behav Neurosci 1985, 99(6):1066-1073.
29. Boileau I., Dagher A., Leyton M., Gunn R.N., Baker G.B., Diksic M., et al. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006, 63(12):1386-1395.
30. Ebstein R.P., Novick O., Umansky R., Priel B., Osher Y., Blaine D., et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 1996, 12(1):78-80.
31. Jacobs D., Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 1986, 16(2):323-329.
32. Goodwin F.K., Murphy D.L., Brodie H.K., Bunney W.E., et al. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. Biol Psychiatry 1970, 2(4):341-366.
33. Anand A., Verhoeff P., Seneca N., Zoghbi S.S., Seibyl J.P., Charney D.S., et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000, 157(7):1108-1114.
34. Suhara T., Nakayama K., Inoue O., Fukuda H., Shimizu M., Mori A., et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berlin) 1992, 106(1):14-18.
35. Swann A.C., Anderson J.C., Dougherty D.M., Moeller F.G., et al. Measurement of inter-episode impulsivity in bipolar disorder. Psychiatry Res 2001, 101(2):195-197.
36. McElroy S.L., Altshuler L.L., Suppes T., Keck P.E., Frye M.A., Denicoff K.D., et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001, 158(3):420-426.
37. McCormick R.A., Russo A.M., Ramirez L.F., Taber J.I. Affective disorders among pathological gamblers seeking treatment. Am J Psychiatry 1984, 141(2):215-218.
38. Hollander E., Pallanti S., Allen A., Sood E., Baldini Rossi N., et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?. Am J Psychiatry 2005, 162(1):137-145.
39. Santos Andrade E.H., Pan P.M., da Silva P.F., Gadelha A., et al. New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature. Case Report Med 2010, 2010. 573252.
40. Hoffer Z.S., Roth R.L., Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009, 50(4):317-324.
41. Ali S., Miller K.K., Freudenreich O. Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics 2010, 51(5):370-376.
42. Cavallaro R., Cocchi F., Angelone S.M., Lattuada E., Smeraldi E., et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004, 65(2):187-190.
43. Pollice R., Di Giovambattista E., Tomassini A., Di Pucchio A., Mazza M., Di Michele V., et al. [Risperidone-induced symptomatic hyperprolactinemia in youth with schizophrenia: efficacy and tolerability of cabergoline treatment]. La Clinica Terapeutica 2007, 158(2):121-126.
44. Tollin S.R. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000, 23(11):765-770.
45. Cohen L.G., Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001, 11(4):435-440.
46. Chang S.C., Chen C.H., Lu M.L. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008, 30(4):378-380.
47. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A., et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96(2):273-288.
48. Brook N.M., Cookson I.B. Bromocriptine-induced mania?. Br Med J 1978, 1(6115):790.
49. Misdrahi D., Chalard R., Verdoux H. [Post partum mania induced by bromocriptine: a case report]. J Gynecol Obstet Biol Reprod (Paris) 2006, 35(1):79-81.
50. Fisher G., Pelonero A.L., Ferguson C. Mania precipitated by prednisone and bromocriptine. Gen Hosp Psychiatry 1991, 13(5):345-346.
51. Johnson J.M. Treated mania exacerbated by bromocriptine. Am J Psychiatry 1981, 138(7):980-982.
52. Vlissides D.N., Gill D., Castelow J. Bromocriptine-induced mania?. Br Med J 1978, 1(6111):510.
53. Kemperman C.J., Zwanikken G.J. Psychiatric side effects of bromocriptine therapy for postpartum galactorrhoea. J Royal Soc Med 1987, 80(6):387-388.
54. Lake C.R., Reid A., Martin C., Chernow B., et al. Cyclothymic disorder and bromocriptine: predisposing factors for postpartum mania?. Can J Psychiatry 1987, 32(8):693-694.
55. Silverstone T. Response to bromocriptine distinguishes bipolar from unipolar depression. Lancet 1984, 1(8382):903-904.
56. Vinkers D.J., van der Wee N.J. A case of mania after long-term use of quinagolide. Gen Hosp Psychiatry 2007, 29(5):464.